Autophagy Mechanisms in Glioma Treatment

Autophagy, a lysosome-mediated degradation pathway, plays a dual role in glioma biology by promoting either cell survival or cell death depending on context and stimulus. In glioma treatment, autophagy is most often activated by temozolomide and other stressors to mitigate genotoxic injury and sustain tumour cell viability. Key regulators include the Beclin-1 complex, microRNAs and cytokine-driven signalling axes such as STAT3. Modulation of autophagy through pharmacological inhibitors (for example chloroquine derivatives) or specific pathway antagonists has shown promise in sensitising resistant tumours. Emerging evidence highlights the importance of glioma stem cells, whose reliance on autophagy can be exploited to overcome therapy resistance and prevent recurrence. Integrated approaches combining standard chemoradiation with autophagy modulators or receptor-targeted biologics offer a route to personalised treatment regimens. As our understanding of autophagic flux and its cross-talk with apoptosis, senescence and the tumour microenvironment grows, so too does the prospect of translating these insights into durable clinical responses against high-grade gliomas.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Autophagy Mechanisms in Glioma Treatment publication trend

The graph below shows the total number of articles in autophagy mechanisms in glioma treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Autophagy: A regulated process by which cells sequester cytoplasmic material in autophagosomes for lysosomal degradation, balancing survival and cell death.

Temozolomide (TMZ): An oral alkylating chemotherapeutic agent that induces DNA methylation and is the standard of care for high-grade gliomas.

Glioma stem cells (GSC): A subpopulation of tumour cells with stem-like properties, including self-renewal and therapy resistance, implicated in recurrence.

MicroRNA (miRNA): Small non-coding RNAs that modulate gene expression post-transcriptionally, influencing pathways such as autophagy and apoptosis.

References

1. Targeting autophagy to sensitive glioma to temozolomide treatment. Journal of Experimental & Clinical Cancer Research (2016).
2. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway. Journal of Hematology & Oncology (2018).
3. A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway. Autophagy (2016).
4. Survival and Death Strategies in Glioma Cells: Autophagy, Senescence and Apoptosis Triggered by a Single Type of Temozolomide-Induced DNA Damage. PLOS ONE (2013).